论文部分内容阅读
目的探讨以米托蒽醌(MTZ)为基础的联合化疗治疗由急性淋巴细胞白血病产生的脏器毒性的临床疗效。方法 110例急性淋巴细胞白血病患者作为研究对象,将其随机分成A组(65例)与B组(45例),A组患者给予MTZ为基础的联合化疗方法进行治疗,B组患者给予以柔红霉素(DNR)为基础的联合化疗方案进行治疗,观察两组患者的治疗效果以及毒副作用情况。结果 A组患者急性淋巴细胞白血病诱导缓解治疗效果明显较B组好(P<0.05),A组患者5年内白血病复发率明显较B组低(P<0.05),两组患者5年内的无病生存率相近,差异无统计学意义(P>0.05);A组患者心脏毒性(心电图、心肌酶、心功能异常)发生率明显较B组低(P<0.05)。结论应用MTZ为基础的联合化疗方案对急性淋巴细胞白血病患者进行治疗,其产生的脏器毒性较小,临床治疗效果较显著,值得临床应用推广。
Objective To investigate the clinical efficacy of combination chemotherapy with mitoxantrone (MTZ) in the treatment of organ toxicity caused by acute lymphoblastic leukemia. Methods One hundred and ten patients with acute lymphoblastic leukemia were randomly divided into group A (n = 65) and group B (n = 45). Patients in group A were treated with MTZ-based combination chemotherapy. Patients in group B Erythromycin (DNR) -based combination chemotherapy was used to treat both groups of patients and to observe the effects and side effects. Results The acute lymphoblastic leukemia induced remission in group A was significantly better than that in group B (P <0.05). The recurrence rate of leukemia in group A was significantly lower than that in group B in 5 years (P <0.05) (P> 0.05). The incidence of cardiotoxicity (ECG, myocardial enzymes, cardiac dysfunction) in group A was significantly lower than that in group B (P <0.05). Conclusion MTZ-based combination chemotherapy regimen for the treatment of patients with acute lymphoblastic leukemia, its organ toxicity is small, the clinical treatment effect is more significant, it is worth promoting the clinical application.